CNTX

Context Therapeutics Inc. (CNTX) | Rumor.io

Context Therapeutics

CNTX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,980

Bullish sentiment (50-day avg)66%

Price to earnings ratio-0.86

Market capitalization30M

Earnings per share-0.48

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-36.1M

Social

What share of all stock conversation is about CNTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 28

The shareholders of Context Therapeutics Inc. have not yet approved a reverse stock split, and the company has a 180-day extension on the NASDAQ listing until January 2027.
The company has a significant cash reserve of 47 cents per share, which could be a stabilizing factor in the event of a reverse stock split or other market volatility.
There are ongoing discussions about the potential for a data readout in Q2 2027, which could be a significant catalyst for the stock price.

Generated by AI

Sentiment

Of the messages about CNTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	80% +20	76.47% +13.14	83.91% +10.85
Bearish	0% 0	20% -20	23.53% -13.14	16.09% -10.85

Bullish· Jan 30

$CNTX is poised for further gains with a strong bullish argument, including potential increases in price and volume.
The asset has shown resilience in a weak market, with a notable bounce back after touching the 20 EMA and a healthy touch of the 30ema.
$CNTX is on track to hit its next target, with key levels of 2.65-2.9 being approached, and the author remains optimistic about the company's potential, comparing it to a similar stock that saw a significant increase in value.

Bearish· Jun 15

The stock's recent performance is concerning, with 11 consecutive days of decline and a significant drop in value.
The company's data readout was met with a negative market reaction, with the stock losing 50% of its value despite positive results.
The stock's decline may be exacerbated by investors' concerns about the company's financial situation, including a need for additional funding and potential dilution.

Generated by AI

Topics

Of the messages about CNTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	76.47%	66.36%
Technical Analysis	—	—	23.53%	19.42%
Analysts	—	—	0%	9.94%
Earnings	—	—	0%	0.36%
Controversies	—	—	0%	0.18%
Macro	—	—	0%	3.74%

Announcements· May 2

Context Therapeutics Inc. ($CNTX) announces FDA clearance of IND application for Phase 1 clinical trial of CTIM-76, a Claudin 6 x CD3 T cell engaging bispecific antibody.
The company expects to enroll the first patient in the dose escalation portion of the clinical trial in mid-2024 and anticipates achieving key program milestones.
Context Therapeutics also announces a $100 million private placement, selling 64.5 million shares of common stock at $1.55 per share, with new and existing investors participating in the deal.

Technical Analysis· Jan 31

The author is focusing on a potential short setup for $CNTX, aiming to target $1.06, but notes that the stock has already bounced off the 150 level.
The author is looking for a breakout level around $1.14 for a move past $1.30, and is also considering a potential pullback or swing in the stock.
The author is expecting a potential retest of the high of day (HOD) at $1.30, and is also looking for a vwap bounce in the stock, with targets at $1.22, $1.31, $1.53, $1.75, and $1.96.

Generated by AI

Community

Of the messages about CNTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	60%	82.89%	49.19%
Newcomers	100%	40%	17.11%	50.81%

Regulars· Aug 28

The author believes Context Therapeutics' (CNTX) data readout in Q2 2027 will show solid results, potentially leading to a significant increase in stock price.
The author is concerned about the high dosing cohort (420 micrograms) in the CNTX trial, as it may be too high, but notes that the patient size in the trial is still significant and there is no more controversy.
The author is optimistic about CNTX's potential, citing the company's solid data and the possibility of a big pharma acquisition, which could lead to a significant increase in stock price.

Newcomers· Jan 5

Newcomers are focused on the potential for Context Therapeutics to increase in value, citing strong short-term growth momentum and the potential for breakthrough progress.
The company's clinical trials and potential for growth are being closely watched, with some users noting the stock's daily gaps and volume as indicators of future performance.
Context Therapeutics is being recommended as a stock to hold and wait for upside potential, with some users citing the company's focus on improving the lives of women with cancer and the potential for breakthrough progress.

Generated by AI

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the P

21d agoYahoo Finance

LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold

Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Context drops bispecific T-cell engager on cost-cutting initiative

1mo agoYahoo Finance

Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Context Therap

Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipeline.

1mo agoBenzinga

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027 PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for t

1mo agoYahoo Finance

Context Therapeutics Receives Nasdaq Minimum Bid Price Notice

Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

Also Discussed

Investors talking about CNTX also mention

#	Name	Attention
1	MRAI - Marpai, Inc.	——
2	Biofrontera Inc.BFRI	0%0
3	Longeveron Inc. Class A Common StockLGVN	0%0
4	Pasithea Therapeutics Corp.KTTA	0%0
5	SGMA - SigmaTron International, Inc.	——
6	PTPI - Petros Pharmaceuticals, Inc.	——
7	Kidpik Corp.PIK	0%new
8	Society Pass IncorporatedSOPA	0%0
9	iSpecimen Inc.ISPC	0%0
10	Ensysce Biosciences, Inc. Common StockENSC	0%0

Context Therapeutics Inc.

Healthcare
Biotechnology

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers. Its current pipeline centers on T cell engaging bispecific antibodies designed to direct immune activity toward cancer cells, including programs targeting CLDN6, mesothelin, and Nectin-4. The company is advancing these candidates through early-stage clinical and preclinical development, with particular attention to cancers such as ovarian, endometrial, and breast cancer. Context Therapeutics Inc. operates as an oncology-focused biotechnology company and works to translate targeted immunotherapy research into potential treatments for genetically and biologically defined patient populations. Headquartered in Philadelphia, Pennsylvania, it remains centered on drug discovery and clinical development rather than commercialized products.

Website

Location

2001 Market Street

Philadelphia, PA, 19103

United States

Social

What share of all stock conversation is about CNTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 28

The shareholders of Context Therapeutics Inc. have not yet approved a reverse stock split, and the company has a 180-day extension on the NASDAQ listing until January 2027.
The company has a significant cash reserve of 47 cents per share, which could be a stabilizing factor in the event of a reverse stock split or other market volatility.
There are ongoing discussions about the potential for a data readout in Q2 2027, which could be a significant catalyst for the stock price.

Generated by AI

Sentiment

Of the messages about CNTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	80% +20	76.47% +13.14	83.91% +10.85
Bearish	0% 0	20% -20	23.53% -13.14	16.09% -10.85

Bullish· Jan 30

$CNTX is poised for further gains with a strong bullish argument, including potential increases in price and volume.
The asset has shown resilience in a weak market, with a notable bounce back after touching the 20 EMA and a healthy touch of the 30ema.
$CNTX is on track to hit its next target, with key levels of 2.65-2.9 being approached, and the author remains optimistic about the company's potential, comparing it to a similar stock that saw a significant increase in value.

Bearish· Jun 15

The stock's recent performance is concerning, with 11 consecutive days of decline and a significant drop in value.
The company's data readout was met with a negative market reaction, with the stock losing 50% of its value despite positive results.
The stock's decline may be exacerbated by investors' concerns about the company's financial situation, including a need for additional funding and potential dilution.

Generated by AI

Topics

Of the messages about CNTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	76.47%	66.36%
Technical Analysis	—	—	23.53%	19.42%
Analysts	—	—	0%	9.94%
Earnings	—	—	0%	0.36%
Controversies	—	—	0%	0.18%
Macro	—	—	0%	3.74%

Announcements· May 2

Context Therapeutics Inc. ($CNTX) announces FDA clearance of IND application for Phase 1 clinical trial of CTIM-76, a Claudin 6 x CD3 T cell engaging bispecific antibody.
The company expects to enroll the first patient in the dose escalation portion of the clinical trial in mid-2024 and anticipates achieving key program milestones.
Context Therapeutics also announces a $100 million private placement, selling 64.5 million shares of common stock at $1.55 per share, with new and existing investors participating in the deal.

Technical Analysis· Jan 31

The author is focusing on a potential short setup for $CNTX, aiming to target $1.06, but notes that the stock has already bounced off the 150 level.
The author is looking for a breakout level around $1.14 for a move past $1.30, and is also considering a potential pullback or swing in the stock.
The author is expecting a potential retest of the high of day (HOD) at $1.30, and is also looking for a vwap bounce in the stock, with targets at $1.22, $1.31, $1.53, $1.75, and $1.96.

Generated by AI

Community

Of the messages about CNTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	60%	82.89%	49.19%
Newcomers	100%	40%	17.11%	50.81%

Regulars· Aug 28

The author believes Context Therapeutics' (CNTX) data readout in Q2 2027 will show solid results, potentially leading to a significant increase in stock price.
The author is concerned about the high dosing cohort (420 micrograms) in the CNTX trial, as it may be too high, but notes that the patient size in the trial is still significant and there is no more controversy.
The author is optimistic about CNTX's potential, citing the company's solid data and the possibility of a big pharma acquisition, which could lead to a significant increase in stock price.

Newcomers· Jan 5

Newcomers are focused on the potential for Context Therapeutics to increase in value, citing strong short-term growth momentum and the potential for breakthrough progress.
The company's clinical trials and potential for growth are being closely watched, with some users noting the stock's daily gaps and volume as indicators of future performance.
Context Therapeutics is being recommended as a stock to hold and wait for upside potential, with some users citing the company's focus on improving the lives of women with cancer and the potential for breakthrough progress.

Generated by AI

Context Therapeutics

Social

Aug 28

Bullish· Jan 30

Bearish· Jun 15

Announcements· May 2

Technical Analysis· Jan 31

Regulars· Aug 28

Newcomers· Jan 5

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold

Context drops bispecific T-cell engager on cost-cutting initiative

Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Context Therap

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Context Therapeutics Receives Nasdaq Minimum Bid Price Notice

Also Discussed

Context Therapeutics Inc.

Company Information

Location

Social

Aug 28

Bullish· Jan 30

Bearish· Jun 15

Announcements· May 2

Technical Analysis· Jan 31

Regulars· Aug 28

Newcomers· Jan 5

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold

Context drops bispecific T-cell engager on cost-cutting initiative

Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Context Therap

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Context Therapeutics Receives Nasdaq Minimum Bid Price Notice

Also Discussed